Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years - United States, July 13, 2022-March 13, 2023.
作者信息
Romanson Brittney, Moro Pedro L, Su John R, Marquez Paige, Nair Narayan, Day Brendan, DeSantis Allison, Shimabukuro Tom T
出版信息
MMWR Morb Mortal Wkly Rep. 2023 Aug 4;72(31):850-851. doi: 10.15585/mmwr.mm7231a4.
Abstract
摘要
相似文献
1
Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years - United States, July 13, 2022-March 13, 2023.实地记录：2022年7月13日至2023年3月13日美国12岁及以上人群中诺瓦瓦克斯新冠疫苗的安全性监测
MMWR Morb Mortal Wkly Rep. 2023 Aug 4;72(31):850-851. doi: 10.15585/mmwr.mm7231a4.
2
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.美国 2022 年 7 月，免疫实践咨询委员会关于 18 岁及以上人群使用 Novavax COVID-19 疫苗的临时建议。
MMWR Morb Mortal Wkly Rep. 2022 Aug 5;71(31):988-992. doi: 10.15585/mmwr.mm7131a2.
3
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023.2023 年 4 月，美国针对≥6 月龄人群使用二价 mRNA COVID-19 疫苗的临时建议。
MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):657-662. doi: 10.15585/mmwr.mm7224a3.
4
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen（强生）和 mRNA COVID-19 疫苗（辉瑞-生物科技和莫德纳）成年受种者发生不良事件后使用 COVID-19 疫苗：免疫实践咨询委员会的更新-美国，2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
5
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.2021年3月至8月美国Moderna、辉瑞-生物科技公司和杨森（强生）疫苗在预防无免疫功能低下状况成年人新冠病毒肺炎住院方面的比较效果
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
6
In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.在未感染过 COVID-19 的成年人中，第二剂接种后≥7 天，Novavax 疫苗的有效性为 90%。
Ann Intern Med. 2022 May;175(5):JC52. doi: 10.7326/J22-0028. Epub 2022 May 3.
7
Preparing for COVID-19 vaccine safety surveillance: A United States perspective.为新冠病毒疫苗安全监测做准备：美国视角
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1529-1531. doi: 10.1002/pds.5142. Epub 2020 Oct 2.
8
Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.2022 年 1 月 12 日至 2022 年 3 月 28 日期间，针对疑似免疫功能低下的≥12 岁人群接种 COVID-19 mRNA 疫苗加强针的安全性监测-美国。
MMWR Morb Mortal Wkly Rep. 2022 Jul 15;71(28):899-903. doi: 10.15585/mmwr.mm7128a3.
9
Notes from the Field: COVID-19 Vaccination Coverage Among Persons Experiencing Homelessness - Six U.S. Jurisdictions, December 2020-August 2021.实地记录：2020年12月至2021年8月美国六个司法管辖区无家可归者的新冠疫苗接种覆盖率
MMWR Morb Mortal Wkly Rep. 2021 Dec 3;70(48):1676-1678. doi: 10.15585/mmwr.mm7048a4.
10
COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021.COVID-19 疫苗接种与非 COVID-19 死亡率风险-2020 年 12 月 14 日至 2021 年 7 月 31 日期间，美国七个综合医疗保健组织。
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520-1524. doi: 10.15585/mmwr.mm7043e2.
引用本文的文献
1
Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea.韩国18岁以上人群中新冠二价mRNA加强疫苗接种的安全性。
Osong Public Health Res Perspect. 2024 Dec;15(6):542-549. doi: 10.24171/j.phrp.2024.0194. Epub 2024 Oct 29.
2
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.新型冠状病毒肺炎（COVID-19）的全面综述：流行病学、发病机制、诊断和检测技术的进展，以及大流行后的治疗策略。
Int J Mol Sci. 2024 Jul 26;25(15):8155. doi: 10.3390/ijms25158155.
3
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.COVID-19 疫苗安全技术（VaST）工作组：在大流行期间加强疫苗安全监测。
Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):125549. doi: 10.1016/j.vaccine.2023.12.059. Epub 2024 Feb 9.
4
COVID-19 Vaccines in Children.儿童新冠疫苗
J Clin Med. 2023 Dec 23;13(1):87. doi: 10.3390/jcm13010087.
本文引用的文献
1
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.美国 2022 年 7 月，免疫实践咨询委员会关于 18 岁及以上人群使用 Novavax COVID-19 疫苗的临时建议。
MMWR Morb Mortal Wkly Rep. 2022 Aug 5;71(31):988-992. doi: 10.15585/mmwr.mm7131a2.
2
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.mRNA COVID-19 疫苗接种后出现心肌炎报告：免疫实践咨询委员会更新-美国，2021 年 6 月。
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
3
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统（VAERS）中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
Zotero 插件